Methods of inhibiting tumor growth and angiogenesis with anastellin

• US 20030091556A1
• Filed: 12/03/2001
• Published: 05/15/2003
• Est. Priority Date: 12/04/2000
• Status: Abandoned Application

• Current Assignee: Burnham Institute For Medical Research
• Original Assignee: Burnham Institute For Medical Research
• Inventors: Yi, Ming, Ruoslahti, Erkki I.
• Application Number:
  US10/005,171
• Publication Number:
  US 20030091556A1
• Time in Patent Office: Days
• US Class Current: 424/94.64
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/363 Fibrinogen
• CPC Class Codes: A61K 38/39 Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
• CPC Class Codes: C07K 14/75 Fibrinogen
• CPC Class Codes: C07K 14/78 Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]

Abstract

The invention provides a substantially pure composition of anastellin (SEQ ID NO: 1) and fibrinogen as well as a substantially pure composition of superfibronectin and superfibrinogen. The invention also provides methods of inhibiting angiogenesis, tumor growth and metastasis by administering anastellin (SEQ ID NO: 1) alone or in combination with fibrinogen.

Claims

1. A substantially pure composition comprising anastellin (SEQ ID NO:

1) and fibrinogen.

2. A substantially pure composition comprising superfibrinogen (sFBG) and superfibronectin (sFN).

3. A method of preparing superfibrinogen (sFBG) comprising contacting fibrinogen with anastellin (SEQ ID NO:

1) under conditions that allow formation of super-fibrinogen (sFBG).

4. A method of inhibiting angiogenesis comprising administering anastellin (SEQ ID NO:

1) in an amount effective to inhibit angiogenesis, wherein said amount is 0.5 mg or greater.

5. A method of inhibiting tumor growth comprising administering anastellin (SEQ ID NO:

1) in an amount effective to inhibit tumor growth, wherein said amount is 0.5 mg or greater.

6. A method of inhibiting angiogenesis comprising administering fibrinogen and a fibrinogen polymerizing agent in an amount effective to inhibit angiogenesis.

7. The method of claim 6, wherein said fibrinogen polymerizing agent is Factor XIIIa.

8. The method of claim 6, wherein said fibrinogen polymerizing agent is anastellin (SEQ ID NO:

1).

9. A method of inhibiting tumor growth comprising administering fibrinogen and a fibrinogen polymerizing agent in an amount effective to inhibit tumor growth.

10. The method of claim 9, wherein said fibrinogen polymerizing agent is Factor XIIIa.

11. The method of claim 9, wherein said fibrinogen polymerizing agent is anastellin (SEQ ID NO:

1).

12. A method of inhibiting metastasis comprising administering fibrinogen and a fibrinogen polymerizing agent in an amount effective to inhibit metastasis.

13. The method of claim 12, wherein said fibrinogen polymerizing agent is Factor XIIIa.

14. The method of claim 12, wherein said fibrinogen polymerizing agent is anastellin (SEQ ID NO:

1).